Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in a standardized neutropenic murine
In the COMBINE pneumonia model, administration of plasma and ELF HSRs of meropenem, cefiderocol and tobramycin demonstrated 24 h cfu/lung within reason of expectation given known PK/PD properties and existing clinical breakpoints.
Authors
- Erin M Duffy (ORCID: https://orcid.org/0000-0002-3319-7554)
- Andrew J Fratoni (ORCID: https://orcid.org/0000-0002-5874-5174)
- David P. Nicolau (ORCID: https://orcid.org/0000-0002-4148-0165)
- Alissa M Padgett
Institutions
- Hartford Hospital (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1093/jac/dkaf100
- Citations
- 2
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- U.S. Department of Health and Human Services
- Bill and Melinda Gates Foundation
- Wellcome Trust
- Public Health Agency of Canada
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
- Department of Health and Social Care
- Public Health Agency
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Novo Nordisk Fonden
- National Institutes of Health
- Biomedical Advanced Research and Development Authority
- National Institute of Allergy and Infectious Diseases